Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on February 3, 2016. The report details a strategic decision by the Board of Directors to reduce operating expenses through a workforce reduction to extend the company's cash runway.
Key Financial Metrics
- Cash Position: As of December 31, 2015, cash, cash equivalents, and short-term investments totaled $55.2 million.
- Exit Costs: The company estimates approximately $0.4 million in cash expenditures related to the workforce reduction, primarily severance costs.
- Liquidity Outlook: Management expects current resources to fund planned operations into the third quarter of 2017.
- Revenue/Profit: The filing text does not provide specific revenue, profit, or margin figures for the reporting period.
Material Changes
- Workforce Reduction: The company committed to reducing its workforce by 11 employees, representing approximately 27% of the total employee base prior to the reduction.
- Operational Adjustments: The company is eliminating certain planned expenditures not required for the completion of ongoing clinical trials.
Guidance, Outlook, and Risks
Clinical Trial Milestones:
- Custirsen (Prostate Cancer): Final analysis of the AFFINITY phase 3 trial expected in Q3 2016.
- Custirsen (Lung Cancer): Final survival analysis of the ENSPIRIT phase 3 trial expected in H1 2017.
- Apatorsen (Bladder Cancer): Final results of the Borealis-2 phase 2 trial expected in H2 2016.
- Apatorsen (Lung Cancer): Overall survival results of the Spruce phase 2 trial expected in H2 2016.
- Regulatory: Preparing an investigational new drug application for apatorsen for intravesical administration.
Risks and Contingencies:
- Forward-looking statements regarding cash adequacy and trial timelines are subject to risks including delays in clinical trials, changes in the cancer therapy landscape, and the inability to raise capital on acceptable terms.
- Product candidates may not demonstrate hypothesized benefits.
Investor Verification Checklist
- Verify the actual cash burn rate post-reduction to confirm the Q3 2017 runway projection.
- Monitor the timing of the AFFINITY and ENSPIRIT trial final analyses against the stated Q3 2016 and H1 2017 targets.
- Confirm the total cost of the workforce reduction remains near the estimated $0.4 million.
- Review upcoming 10-Q filings for updated liquidity positions and any changes to the clinical development plan.